Semaglutide Research for Fatty Liver Disease (MASH)
An evidence-based overview of research examining Semaglutide in the context of fatty liver disease (mash). This page synthesizes findings from peer-reviewed literature.
Research Summary
Semaglutide received FDA approval for metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis in August 2025. The ESSENCE trial showed 62.9% of patients achieved MASH resolution versus 34.3% with placebo, and 36.8% showed fibrosis improvement versus 22.4%. The mechanism involves weight loss and metabolic improvement reducing hepatic fat accumulation and inflammation. The liver, relieved of excess caloric storage burden, can heal and reverse inflammatory damage. This represents a major advance as MASH previously had limited treatment options. The approval covers patients with moderate-to-advanced fibrosis (F2-F3). Long-term outcomes from the ongoing 240-week ESSENCE trial are awaited.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Fatty Liver Disease (MASH)
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Semaglutide may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.